This page will bring together all of the PrescQIPP dermatology resources. Each set of resources includes tools that can be adapted for local use before implementation.
Dermatology - General Resources
In this webinar Lindsay Wilson discusses PrescQIPP resources relating to both emollient and topical corticosteroid prescribing. Sajida Khatri looks at two further PrescQIPP dermatology bulletins on the subjects of Dovobet® in psoriasis, and shampoos and other scalp preparations.
Eczema and Psoriasis
The resources below discuss the use of steroid treatments in eczema and psoriasis, including psoriasis of the scalp.
B116: Topical Corticosteroids
This bulletin discusses the topical steroids used to treat skin conditions such as such as eczema and psoriasis, the bulletin and associated support material focus on ensuring good practice, prescribing appropriate quantities, regular review of topical steroid treatment and rational product selection.
B90: Calcipotriol/Betamethasone (Dovobet) in Psoriasis
This bulletin focuses on the appropriate use of Dovobet® in treating psoriasis and discusses the concerns about long term continuous use. It provides guidance and support for those wishing to review prescribing and ensure it is only used intermittently with safer alternatives. As well as the usual briefing, audit and patient materials, a suggested pathway and aide memoire are also available.
B118: Shampoos and Other Scalp Preparations
This bulletin focuses on shampoos and scalp preparations for the treatment of psoriasis of the scalp and seborrhoeic dermatitis. It discusses appropriate use of these products, including duration of treatment.
Shampoos and Other Scalp Preparations Data Pack
B76: Cost Effective Prescribing of Emollients
Emollients have a key role in treating dry skin conditions, including eczema and psoriasis. This bulletin is intended to guide cost effective and preferred emollient choice when initiating or changing emollient therapy.
Cost-effective and Appropriate Prescribing of Emollients Data Pack
B49: Cost Effective Emollients With No, or Low Paraffin Content
This bulletin discusses issues raised by the NPSA regarding a potential fire risk with the use of paraffin-based emollients. It highlights emollient products which have low or no paraffin content to support healthcare professionals who are optimising emollient treatment in line with the NPSA alert and for patients receiving oxygen therapy.
The following items are on the DROP-List and should be reviewed as they are considered low priority treatments, have little evidence to support their use or can be considered as self care.
B55: Topical Antifungal Nail Treatment Review
This bulletin focuses on topical antifungal nail treatments, i.e. amorolfine 5% nail lacquer (Loceryl®, Curanail®, Omicur®), tioconazole 28% cutaneous solution (Trosyl®) and salicylic acid, tannic acid and boric acid paint (Phytex®) which are low priority treatments. It includes information about the efficacy of both systemic and topical treatments, and discusses when self-care with topical treatments may be considered.
Amorolfine 5% Nail Lacquer Data Pack
B57: Eflornithine Review
This bulletin focuses on eflornithine 11.5% cream, which is a low priority treatment. It recommends that self-funded cosmetic treatments should be the primary option for facial hirsutism for the majority of women.
B60: Minocycline Use in Acne Vulgaris
This bulletin discusses safety concerns relating to the use of minocycline and provides the rationale for new patients to be commenced on an alternative antibiotic and for current patients to be considered for a switch to an alternative antibiotic.